Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-nuclei UPR profiling by flow cytometry reveals bortezomib resistance mechanisms in multiple myeloma.

EMBO molecular medicineĀ·2026
Same author

DIS3 licenses B cells for plasma cell differentiation in humans.

Cellular & molecular immunologyĀ·2025
Same author

Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High-Risk Diffuse Large B Cell Lymphoma.

Hematological oncologyĀ·2025
Same author

Synergistic effect of inhibiting CHK2 and DNA replication on cancer cell growth.

eLifeĀ·2025
Same author

PIM2 inhibition promotes MCL1 dependency in plasma cells involving integrated stress response-driven NOXA expression.

Nature communicationsĀ·2025
Same author

CD38, CD39, and BCL2 differentiate disseminated forms of high-grade B-cell lymphomas in biological fluids from Burkitt lymphoma and diffuse large B-cell lymphoma.

Cytometry. Part B, Clinical cytometryĀ·2024

Related Experiment Video

Updated: Aug 30, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K

Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma.

Sara Ovejero1,2, Jerome Moreaux1,2,3,4

  • 1Department of Biological Hematology, CHU Montpellier, 34295 Montpellier, France.

Exploration of Targeted Anti-Tumor Therapy
|September 1, 2022
PubMed
Summary

Multiple myeloma (MM), a common blood cancer, is complex to treat due to patient variability and drug resistance. Omics technologies are key to developing personalized therapies for better patient outcomes.

Keywords:
Multiple myelomabiomarkersdrugsomics datapersonalized medicinepredictive models

More Related Videos

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

383
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

Related Experiment Videos

Last Updated: Aug 30, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

383
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

Area of Science:

  • Hematologic oncology
  • Genomics and personalized medicine

Background:

  • Multiple myeloma (MM) is the second most common hematologic cancer, characterized by abnormal plasma cell accumulation.
  • Despite therapeutic advances, drug resistance and relapse remain significant challenges in MM patient mortality.
  • The molecular underpinnings of MM are not fully elucidated, contributing to treatment complexities.

Purpose of the Study:

  • To review current therapeutic strategies for multiple myeloma.
  • To highlight the role of high-throughput omics technologies in understanding MM.
  • To discuss the integration of omics data for personalized medicine in MM.

Main Methods:

  • Review of current literature on multiple myeloma treatments.
  • Analysis of the application of omics technologies (genomics, transcriptomics, epigenomics, proteomics, metabolomics) in MM research.
  • Examination of data integration strategies combining omics and clinical data.

Main Results:

  • Omics technologies provide deep insights into MM heterogeneity and molecular mechanisms.
  • Integration of multi-omics data with clinical histories enables risk stratification and treatment response prediction.
  • Personalized predictive models are emerging as crucial for optimizing MM patient care.

Conclusions:

  • Omics-driven personalized medicine represents the future of multiple myeloma treatment.
  • Accurate risk stratification and treatment selection can be achieved through integrated omics data.
  • Continued advancements in omics and data analysis will further improve survival and quality of life for MM patients.